#JPM23: Fire­side chat with Bar­ry Greene: 'There's no straight line to suc­cess'

End­points News founder John Car­roll sat down dur­ing JP Mor­gan with Sage CEO Bar­ry Greene to talk about all things neu­ro. This tran­script has been edit­ed for brevi­ty and clar­i­ty.

John Car­roll:

Bar­ry Greene, the CEO of Sage Ther­a­peu­tics, who af­ter a 17-year run at Al­ny­lam jumped and end­ed up as CEO of a com­pa­ny that’s now look­ing to field its first drug. And I want­ed to talk to you a lit­tle bit about, first of all, what mo­ti­vates you and what mo­ti­vat­ed you to do what you did here in go­ing over to a dif­fer­ent com­pa­ny at that stage in your ca­reer? What was go­ing on? What was the dri­ving fac­tor that got you over to Sage?

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER